Single-Chain Diabodies May Target Variants in Both Solid and Liquid Tumors
Elisa Becze, BA, ELS, Editor
Voice
Description
Lab-developed antibodies using a single-chain diabody format can target TP53 or RAS variants in solid tumors and T-cell receptor (TCR) variants in blood cancers, researchers reported in study findings published in Science, Science Immunology, and Science Translational Medicine, respectively.
ONS Voice Articles
Dive into a rich source of oncology nursing expertise with ONS articles.
View All Voice Articles